PT  - JOURNAL ARTICLE
AU  - SATO, RYO
AU  - MATSUSHITA, YUTO
AU  - TAKEMURA, AYANA
AU  - SUGIYAMA, MOMOKO
AU  - WATANABE, KYOHEI
AU  - WATANABE, HIROMITSU
AU  - TAMURA, KEITA
AU  - MOTOYAMA, DAISUKE
AU  - NAGATA, MASAO
AU  - OTSUKA, ATSUSHI
AU  - FURUSE, HIROSHI
AU  - MIYAKE, HIDEAKI
TI  - Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
AID  - 10.21873/anticanres.16869
DP  - 2024 Feb 01
TA  - Anticancer Research
PG  - 781--786
VI  - 44
IP  - 2
4099  - http://ar.iiarjournals.org/content/44/2/781.short
4100  - http://ar.iiarjournals.org/content/44/2/781.full
SO  - Anticancer Res2024 Feb 01; 44
AB  - Background/Aim: Although the adverse events (AEs) of drugs, such as sunitinib and axitinib, have been shown to predict treatment responses, evidence to support cabozantinib-induced AEs as predictors of responses to treatment for metastatic renal cell carcinoma (mRCC) is limited. Therefore, we herein investigated the relationship between AE profiles and progression-free survival (PFS) in patients receiving cabozantinib for previously treated mRCC. Patients and Methods: The present study retrospectively analyzed 40 patients receiving cabozantinib for previously treated mRCC between July 2020 and August 2022. PFS was estimated using the Kaplan–Meier method and the impact of several parameters, including cabozantinib-induced AEs, on PFS was investigated by a Cox proportional regression analysis. Results: The median observation period was 15 (2-29) months, during which time 31 patients (77.5%) progressed, with median PFS of 11 months. Thirty-nine patients (97.5%) developed at least one AE. Liver toxicity occurred in 16 patients (40.0%) and hand-foot syndrome, hypertension, and diarrhea in 14 each (17.5%). Only hypertension correlated with longer PFS. A multivariate analysis identified hypertension as an independent prognostic factor for PFS (p=0.049). Conclusion: These results suggest the potential of treatment-induced hypertension as a significant predictor of prolonged PFS in patients receiving cabozantinib for mRCC.